Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation

Clinical Transplantation

Volumn 16, Issue 2, 2002, Pages 102-106

  Sugawara, Y ^a,b   Makuuchi, M ^a   Kaneko, J ^a   Ohkubo, T ^a   Imamura, H ^a   Kawarasaki, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Infusion; Living donor liver transplantation; Tacrolimus

Indexed keywords

AMOXICILLIN; CEFOTAXIME; FLUCONAZOLE; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; MULTIVITAMIN; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; BILE DUCT ATRESIA; CHILD; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GRAFT REJECTION; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LIVER WEIGHT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NEUROTOXICITY; POSTOPERATIVE CARE; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RECIPIENT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; ORGAN SIZE; TACROLIMUS;

EID: 0036232105     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2002.1o106.x     Document Type: Article

References (16)

1. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults
2. Initial experience with living-related liver transplantation at the University of Tokyo
3. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation
4. Technical advances in living-related liver transplantation
5. Donor hepatectomy for living related partial liver transplantation
6. Calculation of child and adult standard liver Volume for liver transplantation
7. The evolution of immunosuppression with FK506 in pediatric living-related transplantation
8. Neurologic complications of FK 506
9. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection
10. The impact of donor age on living donor liver transplantation
11. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver
12. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion
13. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450, 3A enzymes in rat, dog and human liver microsomes
14. Isolation identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone
15. Erythromycin breath test and clinical transplantation
16. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation